Shares of Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) were up 1% on Friday . The stock traded as high as $7.76 and last traded at $7.76. Approximately 306 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 2,792 shares. The stock had previously closed at $7.68.
Clinuvel Pharmaceuticals Price Performance
The business has a 50 day moving average price of $7.42 and a 200-day moving average price of $8.52.
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Recommended Stories
- Five stocks we like better than Clinuvel Pharmaceuticals
- Golden Cross Stocks: Pattern, Examples and Charts
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- 3 Best Fintech Stocks for a Portfolio Boost
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- The Basics of Support and Resistance
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
